Current Standards of Care and Evolving Segment 6 Title: Strategies in Metastatic Triple-Negative Breast Cancer

The treatment landscape for metastatic triple-negative breast cancer (TNBC) continues to evolve, guided by NCCN recommendations and emerging clinical evidence. First-line therapy is increasingly influenced by biomarker status, with immunotherapy playing a central role for eligible patients, particularly in combination with chemotherapy. Treatment selection in the frontline setting is shaped by prior therapies, disease burden, and patient-specific factors. In later lines of therapy, antibody–drug conjugates have become a cornerstone of care, with sacituzumab govitecan supported by data from the ASCENT trial as a preferred option following disease progression. Clinicians must also consider tolerability, comorbidities, and patient preferences when sequencing therapies. Early identification of treatment resistance—through clinical progression, lack of response, or worsening symptoms—is critical to optimizing outcomes and timely transitions to alternative therapeutic strategies in this aggressive disease setting.